The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The first step to contact dermatitis treatment is to pinpoint the trigger. Learn when steroid creams help and could make ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults ...

Skin conditions are more common than you might think, with perioral dermatitis being one of the most prevalent.

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can mean a heightened ...

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated ... three dose levels of subcutaneously administered ...